On June 29, Tempus AI rose 5.42% in regular trading, trading at $59.18/share, with turnover of $291 million. The rally was driven by a newly announced collaboration with Angiosarcoma on rare cancer research, further expanding the company's precision medicine footprint amid broad strength in the AI healthcare sector.

The Angiosarcoma partnership, disclosed on June 25, adds to a string of recent catalysts. Tempus AI launched its next-generation Agentic AI platform Lens for oncology drug development in early June, designed to help teams design better clinical trials and target patient subgroups. In late May, the company received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform, making it the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling, with an estimated $200 increase in average selling price expected starting next year. Additionally, an expanded strategic collaboration with Bristol-Myers Squibb across five initial clinical trial programs in solid tumor oncology reinforces the company's commercial momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)